Italian Entrepreneur Launches KAMPOS, A 100% Sustainable, Eco-Friendly Luxury Apparel Brand
KAMPOS , an Italian startup company, today announced the launch of a socially-responsible, environmentally friendly line of products and accessories to celebrate the history and beauty of the Mediterranean Sea. Founded by entrepreneur Alessandro Vergano, KAMPOS’ corporate vision is to “offer luxury products with a conscience, now and for generations to come.” All products are made of recycled plastic bottles, abandoned “ghost” fishing nets, or other recycled nylon and/or organic fabrics. Every product and accessory detail have been studied and designed to be sustainable. KAMPOS’ products are recycled AND are recyclable after use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005003/en/
KAMPOS Red Coral men's swimsuit (Photo : KAMPOS)
“Fashion companies have a tremendous platform from which to reach consumers in a positive manner, but few have embraced social issues as part of their business model,” said Vergano, KAMPOS’ co-founder and chief executive officer. “KAMPOS is different in that sustainability is at the core of everything we do from the selection from raw materials to product development to packaging. This means consumers will realize long-lasting performance of the products in which they invest because of enhanced durability and will be acting in a socially responsible manner with each purchase.”
Vergano’s vision for KAMPOS is to raise awareness worldwide of the impact of plastic pollution and abandoned fishing nets by offering sustainable, alternative high fashion solutions for consumers who share in the company’s mission. A percentage of KAMPOS’ revenues will be donated One Ocean Foundation (https://www.1ocean.org/en/), a non-profit founded in Porto Cervo, Sardinia. The joint effort is to accelerate solutions to ocean issues promoting a sustainable blue economy and enhancing knowledge through ocean literacy.
KAMPOS’ initial product line, which is all made in Italy, consists of swimsuits, shirts, t-shirts, perfumes, sunglasses, pareos (wraparounds) and accessories for men, women, and children. The company’s products are made of: Econyl, 100% regenerated nylon (filament) or certified GOTS (Global Organic Textile Standard) organic and biological cotton; and Newlife™, a unique, certified system of recycled polyester filament yarns that are 100% post-consumer bottle sourced, processed into a polymer through a mechanical -- not chemical -- process, and spun into yarn. No plastic is used in the packaging. The product line is now officially online at www.kampos.com and will be available for purchase in May. In June, KAMPOS plans to open its initial store in Porto Cervo, Sardinia (Italy) at the prestigious Promenade Du Port.
The name KAMPOS is an abbreviation of the Greek word HIPPO KAMPOS, which translates into Seahorse. In Rome and Greek cultures, the Seahorse was sacred to Neptune and Poseidon, the Sea Gods. It was considered a symbol of power, authority and good fortune with strong emotions and intuitions. Vergano launched KAMPOS in homage to his heritage and to celebrate the Mediterranean lifestyle.
KAMPOS’ innovative luxury fashion line includes active involvement from some of Italy’s more prominent creative and photography talent including the Carla Pozzi Agency and Art Director Roberto Da Pozzo in Milan. Additional information about KAMPOS, its products and accessories, are available on Pinterest, Instagram, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005003/en/
Contact information
For more information regarding Kampos from media and/or key influencers, please contact:
Dan Springer
Communications Director
KAMPOS
dan.springer@kampos.com
Ph. +0118587909551 (US)
(Also available via WhatsApp and Google Hangouts)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom